Back
MDCDA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Medlab Clinical Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
3
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Medlab Clinical Limited
📈 Performance
Price History
+6042.86%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$12.90
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in MDCDA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in MDCDA
N/A
MDCDA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in MDCDA also invest in...
Want more shares? Try these...
Medlab Clinical Ltd. is a biotechnology company, which engages in the development of nutraceutical products for chronic diseases and mental health conditions. The company is headquartered in Alexandria, New South Wales. The firm specializes in the application of NanoCelle drug delivery technology to existing and new pharmaceuticals with the objective of empowering patients with chronic diseases and mental health conditions and enhancing their lives. Its drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress. The company also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. The company is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas.
🙌 Performance (5Yr p.a)
-13.93%
📊 Share price
$6.60 AUD
🧬 BIOTECHNOLOGY